Apellis Pharmaceuticals, Inc. (APLS) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
APLS Revenue Growth
Revenue Breakdown (FY 2025)
APLS's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
APLS Revenue Analysis (2014–2025)
As of May 8, 2026, Apellis Pharmaceuticals, Inc. (APLS) generated trailing twelve-month (TTM) revenue of $1.03 billion, reflecting strong growth of +15.1% year-over-year. The most recent quarter (Q1 2026) recorded $192.0 million in revenue, down 4.0% sequentially.
Looking at the longer-term picture, APLS's 5-year compound annual growth rate (CAGR) stands at +32.0%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $1.00 billion in 2025, representing a new all-time high.
Revenue diversification analysis shows APLS's business is primarily driven by Product (69%), and Licensing And Other Revenue (31%). With over half of revenue concentrated in Product, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including RARE (+13.3% YoY), BEAM (+108.0% YoY), and INVA (+13.6% YoY), APLS has underperformed the peer group in terms of revenue growth. Compare APLS vs RARE →
APLS Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| APLSCurrent | $1.0B | +15.1% | +32.0% | 5.5% | |
 RARE | $673M | +13.3% | +19.9% | -79.5% | |
 BEAM | $140M | +108.0% | +466.3% | -274.6% | |
 INVA | $425M | +13.6% | +4.8% | 38.5% | |
 BCAB | $2M | -81.8% | +36.1% | -2965.3% |
APLS Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $1.00B | +28.5% | $901.5M | 89.8% | $55.4M | 5.5% |
| 2024 | $781.4M | +97.0% | $663.6M | 84.9% | $-164,979,000 | -21.1% |
| 2023 | $396.6M | +425.8% | $338.1M | 85.2% | $-517,121,000 | -130.4% |
| 2022 | $75.4M | +13.3% | $69.8M | 92.5% | $-594,613,000 | -788.4% |
| 2021 | $66.6M | -73.4% | $61.4M | 92.2% | $-536,277,000 | -805.7% |
| 2020 | $250.6M | - | $225.6M | 90.0% | $-213,726,000 | -85.3% |
| 2019 | $0 | - | $-595,449 | - | $-288,015,253 | - |
| 2018 | $0 | - | $-127,925,000 | - | $-127,925,000 | - |
| 2017 | $0 | - | $-50,767,000 | - | $-50,767,000 | - |
| 2016 | $0 | - | $0 | - | $-27,282,000 | - |
See APLS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs APLS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare APLS vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonAPLS — Frequently Asked Questions
Quick answers to the most common questions about buying APLS stock.
Is APLS's revenue growth accelerating or slowing?
APLS revenue is accelerating at +15.1% year-over-year, exceeding the 5-year CAGR of +32.0%. TTM revenue reached $1.0B. Growth momentum has increased versus prior periods.
What is APLS's long-term revenue growth rate?
Apellis Pharmaceuticals, Inc.'s 5-year revenue CAGR of +32.0% reflects the sustained expansion pattern. Current YoY growth of +15.1% is above this long-term average.
How is APLS's revenue distributed by segment?
APLS reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.